Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aytu Biopharma Inc (NQ: AYTU )

2.430 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 2.430
Bid (Size) 2.300 (10)
Ask (Size) 2.510 (5)
Prev. Close 2.430
Today's Range 2.430 - 2.430
52wk Range 1.560 - 3.500
Shares Outstanding 5,567,490
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024
Via ACCESSWIRE
Sidoti Events, LLC's Virtual August Micro-Cap Conference
Via ACCESSWIRE

Performance

YTD
-15.92%
-15.92%
1 Month
+2.53%
+2.53%
3 Month
-18.73%
-18.73%
6 Month
-21.10%
-21.10%
1 Year
+50.00%
+50.00%

More News

Read More
Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024
Via ACCESSWIRE
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations
Via ACCESSWIRE
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
Via ACCESSWIRE
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
Via ACCESSWIRE
Earnings Scheduled For February 14, 2024
Via Benzinga
Earnings Preview: Aytu BioPharma
Via Benzinga
Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
Via ACCESSWIRE
Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024
Via Newsfile
Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
Via ACCESSWIRE
AYTU Stock Earnings: Aytu BioPharma Beats EPS, Beats Revenue for Q3 2024
Via InvestorPlace
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
Via ACCESSWIRE
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
Via ACCESSWIRE
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
Via ACCESSWIRE
Aytu BioPharma's Earnings: A Preview
Via Benzinga
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year
Via ACCESSWIRE
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
Via ACCESSWIRE
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023
Via ACCESSWIRE
Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
Via ACCESSWIRE
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Biggest Short Squeeze Stocks Of The Week: Biotech Stocks Dominate, A Bitcoin-Related Stock Moves Up Leaderboard
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.